EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome

Francesca Palandri iD, Massimo Breccia iD, Camilla Mazzoni iD, Giuseppe Auteri, Elena Maria Elli iD, Malgorzata M Trawinska, Nicola Polverelli iD, Mario Tiribelli iD, Giulia Benevolo iD, Alessandra Iurlo iD, Alessia Tieghi, Florian H Heidel und 28 weitere

Cancer · 2023

DOI: 10.1002/cncr.34722 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Francesca Palandri und 39 weiteren Autor:innen. Beteiligte Einrichtung: Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Thrombocytopenia, Anemia, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared with patients with the myeloproliferative phenotype. Aims and Methods Prognostic correlates of cytopenic phenotype were explored in 886 ruxolitinib‐treated patients with primary/secondary MF (PMF/SMF) included in the RUX‐MF retrospective study. Cytopenia was defined as: leukocyte count

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisThrombocytopeniaAnemiaDrug-Related Side Effects and Adverse ReactionsMaleFemaleHumansRetrospective StudiesNitrilesPyrazolesPyrimidines

Stichwörter der Autor:innen

cytopeniamyelodepletive phenotypemyelofibrosismyeloproliferative neoplasmsruxolitinib

Substanzen

ruxolitinibNitrilesPyrazolesPyrimidines

Autor:innen und Institutionen

  • Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Division of Cellular Biotechnologies and Hematology, University Sapienza, Rome, Italy.
  • Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
  • Hematology Division, San Gerardo Hospital, ASST Monza, Monza, Italy.
  • Hematology, Sant'Eugenio Hospital, Tor Vergata University, Roma, Italy.
  • Unit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili di Brescia, Brescia, Italy.

ORCID-Profile: Francesca Palandri, Massimo Breccia, Camilla Mazzoni, Elena Maria Elli, Nicola Polverelli, Mario Tiribelli, Giulia Benevolo, Alessandra Iurlo, Novella Pugliese, Elisabetta Abruzzese, Massimiliano Bonifacio

Förderung

  • Ministero della Salute

Zitieren

APA

Palandri, F., Breccia, M., Mazzoni, C., Auteri, G., Elli, E. M., Trawinska, M. M., Polverelli, N., Tiribelli, M., Benevolo, G., Iurlo, A., Tieghi, A., Heidel, F. H., Caocci, G., Beggiato, E., Binotto, G., Cavazzini, F., Miglino, M., Bosi, C., Crugnola, M., …, & Palumbo, G. A. (2023). Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Cancer. https://doi.org/10.1002/cncr.34722

Vancouver

Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EM, Trawinska MM, et al. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Cancer. 2023. doi:10.1002/cncr.34722

BibTeX
@article{Palandri2023,
  author = {Palandri, Francesca and Breccia, Massimo and Mazzoni, Camilla and Auteri, Giuseppe and Elli, Elena Maria and Trawinska, Malgorzata M and Polverelli, Nicola and Tiribelli, Mario and Benevolo, Giulia and Iurlo, Alessandra and Tieghi, Alessia and Heidel, Florian H and Caocci, Giovanni and Beggiato, Eloise and Binotto, Gianni and Cavazzini, Francesco and Miglino, Maurizio and Bosi, Costanza and Crugnola, Monica and Bocchia, Monica and Martino, Bruno and Pugliese, Novella and Biondo, Mattia and Venturi, Marta and Scaffidi, Luigi and Isidori, Alessandro and Cattaneo, Daniele and Krampera, Mauro and Pane, Fabrizio and Cilloni, Daniela and Semenzato, Gianpietro and Lemoli, Roberto M and Cuneo, Antonio and Abruzzese, Elisabetta and Bartoletti, Daniela and Paglia, Simona and Vianelli, Nicola and Cavo, Michele and Bonifacio, Massimiliano and Palumbo, Giuseppe A},
  title = {Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34722}
}
Kostenlos starten →